Roche Shares Up

Financially, Roche’s core medicines—Hemlibra, Phesgo, and Gazyva—continue to support revenue streams, with the company’s shares up 3 % year‑to‑date against an industry decline of 5.5 %. The combined clinical advances and sales momentum are expected to underpin investor expectations for a strong future outlook, while the fenebrutinib safety data will be closely scrutinised by regulators as the company moves toward global submissions.